A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer

Inclusion Criteria: * Willing and able to provide written informed consent and HIPAA authorization for the release of personal health information or have their legally authorized representative provide written informed consent. A signed informed consent must be obtained prior to performing screening procedures. NOTE: HIPAA authorization may be either included in the informed consent or obtained separately * Males 18 years of age or above * Histologically or cytologically confirmed adenocarcinoma of the prostate * Bilateral orchiectomy or ongoing androgen deprivation therapy with a GnRH agonist/antagonist (surgical or medical castration) * Progression of mCRPC on treatment with at least 1 second generation hormonal agent (e.g., enzalutamide and/or abirateroneacetate/prednisone) * Documented progressive mCRPC based on at least one of the following criteria: * PSA progression defined as at least 2 rises in PSA with a minimum of a 1-week interval * 1.0 ng/mL is the minimal starting value if confirmed rise is only indication of progression * Soft-tissue progression per RECISTv1.1 * Progression of bone disease (evaluable disease) or tow or more new bone lesions by bone scan * Metastatic disease documented by bone lesions on whole-body radionuclide bone scan or soft tissue disease by computed tomography/magnetic-resonance imaging (CT/MRI). * Consent to a fresh tumor biopsy during screening or have sufficient archival tumor tissue available for molecular profile and bioma…